Candel Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Candel Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 27.4% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Candel Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2024 | N/A | -50 | -31 | -31 | N/A |
3/31/2024 | N/A | -37 | -32 | -32 | N/A |
12/31/2023 | N/A | -38 | -35 | -34 | N/A |
9/30/2023 | 0 | -32 | -34 | -34 | N/A |
6/30/2023 | 0 | -32 | -35 | -34 | N/A |
3/31/2023 | 0 | -27 | -35 | -34 | N/A |
12/31/2022 | 0 | -19 | -33 | -31 | N/A |
9/30/2022 | 0 | -12 | -31 | -30 | N/A |
6/30/2022 | 0 | -20 | -29 | -27 | N/A |
3/31/2022 | 0 | -33 | -26 | -25 | N/A |
12/31/2021 | 0 | -36 | -24 | -22 | N/A |
9/30/2021 | 0 | -48 | -22 | -20 | N/A |
6/30/2021 | 0 | -35 | -17 | -15 | N/A |
3/31/2021 | 0 | -20 | -14 | -12 | N/A |
12/31/2020 | 0 | -18 | -11 | -9 | N/A |
12/31/2019 | 0 | -8 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CADL's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if CADL's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CADL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CADL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CADL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CADL's Return on Equity is forecast to be high in 3 years time